EIM
ARQT icon

Essex Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Essex Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.39M Buy
143,934
+2,663
+2% +$68K 0.54% 64
2025
Q4 		$4.1M Sell
141,271
-54,991
-28% -$1.41M 0.63% 56
2025
Q3 		$3.7M Buy
196,262
+6,751
+4% +$106K 0.57% 59
2025
Q2 		$2.66M Sell
189,511
-1,127
-0.6% -$15.8K 0.48% 85
2025
Q1 		$2.98M Buy
190,638
+47,815
+33% +$674K 0.62% 53
2024
Q4 		$1.99M Sell
142,823
-21,141
-13% -$232K 0.36% 120
2024
Q3 		$1.52M Buy
163,964
+403
+0.2% +$3.98K 0.27% 135
2024
Q2 		$1.52M Buy
+163,561
New +$1.48M 0.28% 131

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Essex Investment Management's ARQT Position: Q1 2026 in Review

Essex Investment Management increased its Arcutis Biotherapeutics (ARQT) stake by 1.9% in Q1 2026, buying an estimated $68K and bringing the position to 143,934 shares worth $3.39M. The position accounts for 0.54% of the portfolio, ranked #64.

Essex Investment Management first reported a position in ARQT in Q2 2024 and has held it in 8 quarters since. The position peaked at $4.1M in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Essex Investment Management held 143,934 shares of Arcutis Biotherapeutics worth $3.39M as of Q1 2026.
  • Essex Investment Management bought 2,663 Arcutis Biotherapeutics shares in Q1 2026, an estimated $68K.
  • Arcutis Biotherapeutics made up 0.54% of Essex Investment Management's portfolio in Q1 2026, its #64 holding.
  • Essex Investment Management first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 8 quarters since.
  • Essex Investment Management's Arcutis Biotherapeutics position peaked at $4.1M in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Essex Investment Management's 13F filing for Q1 2026, filed 11 May 2026.